Methotrexate in Rheumatoid Arthritis: Efficacy and Toxicity Management
Role of Methotrexate in RA Treatment
- The American College of Rheumatology recommends methotrexate as the anchor drug for rheumatoid arthritis and should be used first-line in patients at risk of developing persistent or erosive disease 1, 2, 3
- Methotrexate serves as the foundation for combination therapy with TNF blockers, producing maximum therapeutic effect when combined with biologics 1, 2, 4
- Leflunomide and sulfasalazine are the best alternatives when methotrexate is contraindicated, though sulfasalazine may be inferior long-term 1, 3
- Methotrexate monotherapy is nearly as effective as TNF blocker monotherapy in early severe RA (disease duration <3 years) 1, 2
Optimal Dosing and Administration
- The optimal starting dose of methotrexate is 10-15 mg weekly, escalated by 5 mg every 2-4 weeks to reach 20-30 mg weekly based on response and tolerability 5, 6, 7
- Higher starting doses (25 mg/week) show greater efficacy but trend toward more gastrointestinal toxicity compared to 15 mg/week 5, 6
- Rapid escalation (5 mg/month to 25-30 mg/week) achieves higher efficacy but increases adverse events compared to slow escalation 5, 6
- The evidence-based optimal strategy: start at 15 mg/week orally, escalate by 5 mg/month to 25-30 mg/week or the highest tolerable dose 6
Pre-Treatment Work-Up and Monitoring
- Before starting methotrexate, obtain: AST, ALT, albumin, CBC, creatinine, chest X-ray (within past year), and assess risk factors including alcohol intake 5, 7
- Consider additional testing: hepatitis B/C serology, HIV serology, fasting glucose, lipid profile, and pregnancy test 5
- Tuberculosis screening should be performed if biologics are anticipated 4
- When initiating or escalating methotrexate, check ALT (with or without AST), creatinine, and CBC every 1-1.5 months until dose is stable, then every 1-3 months thereafter 5, 7
Toxicity Prevention and Management
- Prescribe at least 5 mg folic acid weekly with methotrexate therapy—this is a strong recommendation 5, 7
- Folic acid significantly reduces methotrexate toxicity, particularly gastrointestinal side effects and mucosal toxicity 5, 7
- Patients with interstitial lung disease can be conditionally used in those with mild, stable ILD and moderate-to-high RA activity, but inform patients of increased pneumonitis risk 7